Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1579428
Sentiment: neutral
Topics: corporate-filing, sec-filing, 8-k
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K on 8/21/24, updating corporate info and filings.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on August 21, 2024, reporting other events and financial statements/exhibits. The filing details the company's principal executive offices located at One World Trade Center, New York, NY, and its primary business in Pharmaceutical Preparations.
Why It Matters
This 8-K filing serves as an official record of significant corporate events and financial disclosures for Axsome Therapeutics, Inc., providing transparency to investors and the public.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Numbers
- 001-37635 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-4241907 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- August 21, 2024 (date) — Date of earliest event reported
- One World Trade Center, 22nd Floor (location) — Principal Executive Offices
- New York, New York (location) — Principal Executive Offices City and State
- 10007 (postal_code) — Principal Executive Offices Zip Code
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 21, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 21, 2024.
Where are Axsome Therapeutics, Inc.'s principal executive offices located?
Axsome Therapeutics, Inc.'s principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.
What is the company's SEC file number?
The company's SEC file number is 001-37635.
What is the Standard Industrial Classification for Axsome Therapeutics, Inc.?
The Standard Industrial Classification for Axsome Therapeutics, Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2024-08-21 07:05:55
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20240821.htm (8-K) — 39KB
- axsm-ex99_1.htm (EX-99.1) — 16KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-099389.txt ( ) — 196KB
- axsm-20240821.xsd (EX-101.SCH) — 23KB
- axsm-20240821_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 21, 2024, Axsome Therapeutics, Inc. issued a press release announcing that it has reached agreement with Sandoz Inc. to dismiss the patent litigation related to Axsome's product Sunosi (solriamfetol). The full text of the press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: August 21, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer